Sanofi-Aventis Hasn't Got Genzyme in the Bag Yet

Sanofi has bought itself more time but we still think it undervalues Genzyme and a second bidder could yet emerge

Karen Andersen, CFA 14 December, 2010 | 3:15PM
Facebook Twitter LinkedIn

Sanofi-Aventis announced on Monday that it has extended its $69 per share hostile offer for Genzyme shares from the previous Dec. 10 deadline until Jan. 21. This was not an unexpected development, and while it pushes a final deal into 2011, we don't think it changes the dynamics of the negotiation. As we've stated before, we think Sanofi undervalues Genzyme's pipeline, particularly Campath in multiple sclerosis, and we continue to believe that our $78 fair value estimate remains a reasonable level for a final deal.

Sanofi's initial $69 per share offer for Genzyme was both officially confirmed and rejected, and Sanofi opted to go hostile in October, appealing directly to Genzyme shareholders with the same offer that was rejected by Genzyme's board. As we expected, shareholders were not amenable to this price (less than 1% of shares were tendered by the December 10 expiration of the tender offer), and we see the extended offer as likely to bring both firms back to the negotiating table to agree on a higher price. We've witnessed a pattern of hostile offers leading to increased bids with recent deals in the biotech space, including Roche's acquisition of Genentech and Astellas' acquisition of OSI Pharmaceuticals. An alternative to a higher bid would be the incorporation of a contingent value right into the deal, to account for the discrepancy in Sanofi and Genzyme's valuation of Campath and reward Genzyme shareholders if Campath is indeed commercially successful in multiple sclerosis. Celgene used earnouts related to Abraxane sales and future approvals in its acquisition of Abraxis, and we think such a structure could make sense with a firm like Genzyme, as $13 of our $78 fair value estimate relies on future cash flow from MS drug candidate Campath.

As we've discussed previously, there also remains the possibility of a second bidder emerging. Johnson & Johnson's and Pfizer's financial health would make it relatively easy for either firm to absorb Genzyme, and GlaxoSmithKline's strategy to increase its orphan drug exposure would receive strong support from Genzyme's established rare disease portfolio. We also consider Amgen a potential suitor. While Amgen's biologic drug focus separates it from its big pharma peers, many of whom are contending with a steep patent cliff over the next few years, its aging portfolio is among the first to face biosimilar competition, and growth prospects are heavily tied to Prolia. Given Amgen's recent slowing of share repurchases, management could be seriously considering an acquisition. While it is likely to be tempted by non-US based biotechs in order to avoid repatriation tax and yet still accomplish its goal of reinvigorating revenue growth, the dearth of internationally-based targets that make sense for the firm could still lead it to consider Genzyme, in our view.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Karen Andersen, CFA  Karen Andersen, CFA, is a senior stock analyst with Morningstar.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies       Modern Slavery Statement